Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangshen'an is an investigational Traditional Chinese Medicine (TCM) formulation, typically administered as a granule, developed for the treatment of diabetic neurovascular coupling impairment (NCI). NCI is a critical pathological mechanism in diabetes where the coordination between neural activity and regional blood flow (in the brain and eyes) is disrupted, potentially leading to cognitive decline and retinopathy. Tangshen'an is being evaluated in clinical trials (such as NCT06124898) using advanced eye-brain multimodal imaging to quantify its impact on neurovascular function. The development is primarily associated with researchers at the Beijing University of Chinese Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tangshen'an (Beijing University of Chinese Medicine).